Trabectedin

DB05109

small molecule approved investigational

Deskripsi

Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.

Struktur Molekul 2D

Berat 761.837
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 33-50 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Administered intravenously.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

3 Data
  • 1. Avoid alcohol. There may be an additive hepatotoxic effect if alcohol and trabectedin are coadministered.
  • 2. Avoid St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce the serum concentration of trabectedin.
  • 3. Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of trabectedin.

Interaksi Obat

1284 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Trabectedin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trabectedin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Trabectedin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Trabectedin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Trabectedin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Trabectedin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trabectedin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trabectedin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trabectedin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trabectedin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Trabectedin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Trabectedin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Trabectedin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trabectedin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Trabectedin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trabectedin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Trabectedin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Trabectedin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trabectedin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trabectedin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Trabectedin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trabectedin.
Cladribine Trabectedin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Trabectedin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Trabectedin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Trabectedin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Trabectedin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Trabectedin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Trabectedin.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Trabectedin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Trabectedin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trabectedin.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Trabectedin.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Trabectedin.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Trabectedin.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Trabectedin.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Trabectedin.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trabectedin.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Trabectedin.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trabectedin.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Trabectedin.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Trabectedin.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Trabectedin.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Trabectedin.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Trabectedin.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Trabectedin.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Trabectedin.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Trabectedin.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Trabectedin.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trabectedin.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Trabectedin.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Trabectedin.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Trabectedin.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Trabectedin.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Trabectedin.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Trabectedin.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Trabectedin.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Trabectedin.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Trabectedin.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trabectedin.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Trabectedin.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Trabectedin.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Trabectedin.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Trabectedin.
Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Trabectedin.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Trabectedin.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Trabectedin.
Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Trabectedin.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Trabectedin.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Trabectedin.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Trabectedin.
Stepronin The risk or severity of adverse effects can be increased when Stepronin is combined with Trabectedin.
Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Trabectedin.
Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Trabectedin.
2-Methoxyethanol The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Trabectedin.
Brequinar The risk or severity of adverse effects can be increased when Brequinar is combined with Trabectedin.
Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Trabectedin.
Aldosterone The risk or severity of adverse effects can be increased when Aldosterone is combined with Trabectedin.
Pirfenidone The metabolism of Trabectedin can be decreased when combined with Pirfenidone.
Interferon alfa The risk or severity of adverse effects can be increased when Trabectedin is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Trabectedin is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Trabectedin is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Trabectedin is combined with Human interferon omega-1.
Mepolizumab The risk or severity of adverse effects can be increased when Trabectedin is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Trabectedin is combined with Abetimus.
Belatacept The risk or severity of adverse effects can be increased when Trabectedin is combined with Belatacept.
Bendamustine The risk or severity of adverse effects can be increased when Trabectedin is combined with Bendamustine.
Cabazitaxel The risk or severity of adverse effects can be increased when Trabectedin is combined with Cabazitaxel.
Pralatrexate The risk or severity of adverse effects can be increased when Trabectedin is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Trabectedin is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Trabectedin is combined with Eribulin.
Belimumab The risk or severity of adverse effects can be increased when Trabectedin is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Trabectedin is combined with Teriflunomide.
Carfilzomib The risk or severity of adverse effects can be increased when Trabectedin is combined with Carfilzomib.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Trabectedin is combined with Dimethyl fumarate.
Pomalidomide The risk or severity of adverse effects can be increased when Trabectedin is combined with Pomalidomide.
Obinutuzumab The risk or severity of adverse effects can be increased when Trabectedin is combined with Obinutuzumab.
Vedolizumab The risk or severity of adverse effects can be increased when Trabectedin is combined with Vedolizumab.
Blinatumomab The risk or severity of adverse effects can be increased when Trabectedin is combined with Blinatumomab.
Dinutuximab The risk or severity of adverse effects can be increased when Trabectedin is combined with Dinutuximab.

Target Protein

DNA

Referensi & Sumber

Synthesis reference: Elias J. Corey, David Gin, "Process for producing ecteinascidin compounds." U.S. Patent US5721362, issued December, 1995.
Artikel (PubMed)
  • PMID: 18021177
    Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M: Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif. 2007 Dec;40(6):885-904.
  • PMID: 18000504
    Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME: A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17;97(12):1618-24. Epub 2007 Nov 13.
  • PMID: 17927287
    Carter NJ, Keam SJ: Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs. 2007;67(15):2257-76.
  • PMID: 16922593
    Authors unspecified: Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D. 2006;7(5):317-28.
  • PMID: 19515014
    Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Yondelis
    Injection, powder, for solution • 0.25 mg • Intravenous • EU • Approved
  • Yondelis
    Injection, powder, for solution • 1 mg • Intravenous • EU • Approved
  • Yondelis
    Injection, powder, lyophilized, for solution • 0.05 mg/1mL • Intravenous • US • Approved
  • Yondelis
    Powder, for solution • 1 mg / vial • Intravenous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul